GlobeNewswire: ABIOMED, Inc. Contains the last 10 of 257 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T08:31:23ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2018/11/02/1641996/0/en/Abiomed-to-Present-at-the-Stephens-2018-Investment-Conference-in-New-York-NY.html?f=22&fvtc=4&fvtv=15397Abiomed to Present at the Stephens 2018 Investment Conference in New York, NY2018-11-02T12:00:00Z<![CDATA[DANVERS, Mass., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the Stephens NY Investment Conference on Wednesday, November 7, 2018 at 1:00pm. The conference will be held at the Lotte New York Palace Hotel.]]>https://www.globenewswire.com/news-release/2018/11/02/1641789/0/fr/Abiomed-annonce-un-chiffre-d-affaires-record-de-182-millions-pour-le-deuxi%C3%A8me-trimestre-2019-soit-une-hausse-de-37-par-rapport-au-trimestre-%C3%A9quivalent-de-l-exercice-pr%C3%A9c%C3%A9dent.html?f=22&fvtc=4&fvtv=15397Abiomed annonce un chiffre d'affaires record de 182 millions $ pour le deuxième trimestre 2019, soit une hausse de 37 % par rapport au trimestre équivalent de l'exercice précédent2018-11-02T00:21:24Z<![CDATA[DANVERS, Massachusetts, 02 nov. 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ: ABMD), un fournisseur majeur de technologies innovantes de récupération et d'assistance cardiaque, a annoncé aujourd'hui un chiffre d'affaires de 181,8 millions $ pour le deuxième trimestre de l'exercice 2019, soit une augmentation de 37 % par rapport au chiffre d'affaires de 132,8 millions $ pour le trimestre équivalent de l'exercice 2018. Le bénéfice net PCGR du deuxième trimestre de l'exercice 2019 est de 50,1 millions $, soit 1,09 $ par action après dilution, une hausse de 104 % comparé au bénéfice net PCGR de 24,5 millions $ ou 0,82 $ par action après dilution pour le deuxième trimestre 2018.]]>https://www.globenewswire.com/news-release/2018/11/02/1641789/0/de/Abiomed-k%C3%BCndigt-Rekordumsatz-von-182-Millionen-USD-f%C3%BCr-das-zweite-Quartal-des-Gesch%C3%A4ftsjahres-2019-an-eine-Steigerung-von-37-gegen%C3%BCber-dem-Vorjahr.html?f=22&fvtc=4&fvtv=15397Abiomed kündigt Rekordumsatz von 182 Millionen USD für das zweite Quartal des Geschäftsjahres 2019 an – eine Steigerung von 37 % gegenüber dem Vorjahr2018-11-02T00:21:24Z<![CDATA[DANVERS, Massachusetts, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ: ABMD), ein führender Anbieter bahnbrechender Technologien zur Herzunterstützung und Wiederherstellung der Herzfunktion, vermeldete heute einen Umsatz von 181,8 Millionen USD für das zweite Quartal des Geschäftsjahres 2019, was einem Anstieg von 37 % gegenüber dem Umsatz von 132,8 Millionen USD für den gleichen Zeitraum des Geschäftsjahres 2018 gleichkommt. Der GoB-Reingewinn für das zweite Quartal des Geschäftsjahres 2019 betrug 50,1 Millionen USD bzw. 1,09 USD je verwässerter Aktie, ein Anstieg von 104 % gegenüber dem GoB-Reingewinn von 24,5 Millionen USD bzw. 0,54 USD je verwässerter Aktie im gleichen Zeitraum des Vorjahres.]]>https://www.globenewswire.com/news-release/2018/11/02/1641789/0/ja/%E3%82%A2%E3%83%93%E3%82%AA%E3%83%A1%E3%83%83%E3%83%89-2019%E5%B9%B4%E5%BA%A6%E7%AC%AC2%E5%9B%9B%E5%8D%8A%E6%9C%9F%E3%81%AE%E5%8F%8E%E5%85%A5%E3%82%92%E7%99%BA%E8%A1%A8-%E5%8F%8E%E5%85%A5%E3%81%AF%E5%89%8D%E5%B9%B4%E3%82%9237-%E4%B8%8A%E5%9B%9E%E3%82%8B1%E5%84%848-200%E4%B8%87%E3%83%89%E3%83%AB-%E7%B4%84205%E5%84%84%E5%86%86.html?f=22&fvtc=4&fvtv=15397アビオメッド、2019年度第2四半期の収入を発表、収入は前年を37%上回る1億8,200万ドル (約205億円)2018-11-02T00:21:24Z<![CDATA[マサチューセッツ州ダンバース発, Nov. 02, 2018 (GLOBE NEWSWIRE) -- 画期的な心臓回復およびサポート技術のリーディングプロバイダであるアビオメッド (Abiomed, Inc.、 NASDAQ:ABMD) は本日、2019年度第2四半期に1億8,180万ドル (約205億円) の収入を計上し、2018年度同期の1億3,280万ドル (約150億円) の収入を37%上回ったことを発表した。2019年度第2四半期のGAAP純収益は5,010万ドル (約56憶円) (希薄化後1株当たり1.09ドル (約125円)) であった (前年同期のGAAP純収益は2,450万ドル (約28億円)、希薄後1株当たり0.54ドル (約60円) であった)。]]>https://www.globenewswire.com/news-release/2018/11/01/1640967/0/en/Abiomed-Announces-Q2-FY-2019-Record-Revenue-of-182-Million-up-37-Over-Prior-Year.html?f=22&fvtc=4&fvtv=15397Abiomed Announces Q2 FY 2019 Record Revenue of $182 Million, up 37% Over Prior Year2018-11-01T11:00:00Z<![CDATA[DANVERS, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart recovery and support technologies, today reported second quarter fiscal 2019 revenue of $181.8 million, an increase of 37% compared to revenue of $132.8 million for the same period of fiscal 2018. Second quarter fiscal 2019 GAAP net income was $50.1 million or $1.09 per diluted share, up 104% compared to GAAP net income of $24.5 million or $0.54 per diluted share for the prior year period.]]>https://www.globenewswire.com/news-release/2018/10/11/1619870/0/en/Abiomed-Second-Quarter-Fiscal-2019-Earnings-and-Conference-Call-Notification.html?f=22&fvtc=4&fvtv=15397Abiomed Second Quarter Fiscal 2019 Earnings and Conference Call Notification2018-10-11T12:00:00Z<![CDATA[DANVERS, Mass., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, November 1, 2018, the Company will release financial results for the second quarter of fiscal 2019. The Company will host a conference call to discuss the results on Thursday, November 1, 2018, at 8:00 a.m. EDT. Michael R. Minogue, Chairman, President and Chief Executive Officer, and Todd Trapp, Chief Financial Officer, will host the conference call.]]>https://www.globenewswire.com/news-release/2018/09/24/1574929/0/en/Data-Presented-at-TCT-2018-Shows-Use-of-Impella-and-Best-Practices-Increases-Cardiogenic-Shock-Survival.html?f=22&fvtc=4&fvtv=15397Data Presented at TCT 2018 Shows Use of Impella and Best Practices Increases Cardiogenic Shock Survival2018-09-24T12:00:00Z<![CDATA[SAN DIEGO, Sept. 24, 2018 (GLOBE NEWSWIRE) -- A new analysis of data from Abiomed's (NASDAQ:ABMD) Impella® Quality (IQ) Database shows a relative increase of 24% in mean survival in acute myocardial infarction (AMI) cardiogenic shock patients since Impella’s cardiogenic shock FDA post-market approval. Part of the reason for the increase was a near doubling in the number of hospital centers achieving a greater than 80% survival to explant. This data was presented at the 30th Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego, Calif., by William O’Neill, MD, medical director of the Center for Structural Heart Disease at Henry Ford Hospital in Detroit.]]>https://www.globenewswire.com/news-release/2018/09/19/1573300/0/en/Abiomed-to-Showcase-Expanded-FDA-Indications-and-Next-Generation-Heart-Recovery-Products-at-TCT-2018.html?f=22&fvtc=4&fvtv=15397Abiomed to Showcase Expanded FDA Indications and Next Generation Heart Recovery Products at TCT 20182018-09-19T16:53:14Z<![CDATA[DANVERS, Mass., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), the leader in heart recovery, announces its initiatives at the 30th Transcatheter Cardiovascular Therapeutics (TCT) conference will highlight the recently expanded FDA indications for high-risk PCI and cardiogenic shock. Initiatives will also highlight Protected PCI’s ability to allow for more complete revascularization, which improves outcomes1 and quality of life2,3. More than 30 presentations as well as live cases featuring Impella® heart pumps are expected at TCT 2018, taking place September 21-25 in San Diego, California.]]>The FDA approved Impella CP® with SmartAssist™ includes hemodynamic sensors to intelligently position, manage and wean.Impella CP® with SmartAssist™https://www.globenewswire.com/news-release/2018/07/26/1543142/0/ja/%E3%82%A2%E3%83%93%E3%82%AA%E3%83%A1%E3%83%83%E3%83%89-2019%E5%B9%B4%E5%BA%A6%E7%AC%AC1%E5%9B%9B%E5%8D%8A%E6%9C%9F%E3%81%AE%E5%8F%8E%E5%85%A5%E3%82%92%E7%99%BA%E8%A1%A8-%E5%8F%8E%E5%85%A5%E3%81%AF%E5%89%8D%E5%B9%B4%E5%BA%A6%E6%AF%9436-%E5%A2%97%E3%81%AE1%E5%84%848-000%E4%B8%87%E3%83%89%E3%83%AB.html?f=22&fvtc=4&fvtv=15397アビオメッド、2019年度第1四半期の収入を発表、収入は前年度比36%増の1億8,000万ドル2018-07-26T22:56:28Z<![CDATA[「FDA STEMI DTU」安全およびフィージビリティ調査の組み入れを完了 「FDA STEMI DTU」安全およびフィージビリティ調査の組み入れを完了]]>https://www.globenewswire.com/news-release/2018/07/26/1542587/0/en/Abiomed-Announces-Approval-in-India-for-the-Impella-2-5-Impella-CP-and-Impella-5-0-Heart-Pumps-and-First-Indian-Patient-Treated.html?f=22&fvtc=4&fvtv=15397Abiomed Announces Approval in India for the Impella 2.5®, Impella CP® and Impella 5.0® Heart Pumps and First Indian Patient Treated2018-07-26T11:30:00Z<![CDATA[]]>